Skip to main content

Table 1 Clinicopathological characteristics of patients at diagnosis of epithelial ovarian cancer

From: Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer

Characteristics All (n=128, %) BRCA mutation (n=51, %) BRCA wild-type (n=77, %) P
Age, years
 Mean ± SD 56.4 ± 10.3 54.7 ± 9.9 57.5 ± 10.4 0.130
 <50 39 (30.5) 20 (39.2) 19 (24.7) 0.080
 ≥50 89 (69.5) 31 (60.8) 58 (75.3)
BMI, kg/m2
 Mean ± SD 23.4 ± 3.5 23.2 ± 3.7 23.6 ± 3.5 0.576
CA-125, IU/ml
 Median (range) 921.5 (13.0−10000.0) 795.0 (34.9−9926.0) 1296.0 (13.0−10000.0) 0.724
FIGO stage     0.077
 III 77 (60.2) 38 (74.5) 39 (50.6) 0.007
  IIIA1 4 (3.1) 3 (5.9) 1 (1.3)  
  IIIA2 4 (3.1) 1 (2.0) 3 (3.9)
  IIIB 12 (9.4) 5 (9.8) 7 (9.1)
  IIIC 57 (44.5) 29 (56.9) 28 (36.4)
 IV 51 (39.8) 13 (25.5) 38 (49.4) 0.007
  IVA 6 (4.7) 1 (2.0) 5 (6.5)  
  IVB 45 (35.2) 12 (23.5) 33 (42.9)
Primary treatment strategy     0.846
 PDS 79 (61.7) 32 (62.7) 47 (61.0)  
 NAC 49 (38.3) 19 (37.3) 30 (39.0)
Residual tumor after PDS/IDS     0.192
 Optimal debulking 109 (85.2) 46 (90.2) 63 (81.8)  
 Suboptimal debulking 19 (14.8) 5 (9.8) 14 (18.2)
Recurrence
 No 39 (30.5) 20 (39.2) 19 (24.7) 0.080
 Yes 89 (69.5) 31 (60.8) 58 (75.3)
 Platinum-sensitive recurrence 62 (48.4) 25 (49.0) 37 (48.1) 0.099
 Platinum-resistant recurrence 27 (21.1) 6 (11.8) 21 (27.3)
BRCA mutation
BRCA1 37 (28.9) 37 (72.5)   
BRCA2 14 (10.9) 14 (27.5)  
 Both 0 (0) 0 (0)  
Interval between diagnosis and genetic test, months
 Median (range) 3.5 (0−22.7) 2.6 (0−22.4) 4.3 (0.1−22.7) 0.065
  1. Abbreviations: BMI body mass index, CA-125 cancer antigen 125, FIGO International Federation of Gynecology and Obstetrics, PDS primary debulking surgery, NAC neoadjuvant chemotherapy, IDS interval debulking surgery, SD standard deviation